WM-A1-3389
/ Y-Biologics, WMBIO
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
March 12, 2024
Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)
(clinicaltrials.gov)
- P1 | N=54 | Recruiting | Sponsor: Wellmarker Bio | Not yet recruiting ➔ Recruiting
Combination therapy • Enrollment open • Metastases • Biliary Cancer • Cholangiocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • IGSF1 • PD-L1
October 30, 2023
Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (KEYNOTE-E90)
(clinicaltrials.gov)
- P1 | N=54 | Not yet recruiting | Sponsor: Wellmarker Bio | Trial completion date: Sep 2025 ➔ Feb 2026 | Initiation date: Aug 2023 ➔ Jan 2024 | Trial primary completion date: Sep 2025 ➔ Feb 2026
Combination therapy • Metastases • Trial completion date • Trial initiation date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • PD-L1
May 24, 2023
Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer
(clinicaltrials.gov)
- P1 | N=54 | Not yet recruiting | Sponsor: Wellmarker Bio
Combination therapy • Metastases • New P1 trial • Biliary Cancer • Cholangiocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • PD-L1
February 07, 2023
Wellmarker Bio Announces Clinical Trial Collaboration with MSD to evaluate WM-A1-3389 in combination with KEYTRUDA (pembrolizumab)
(PRNewswire)
- "Wellmarker Bio Co., Ltd...announced the company has entered a clinical trial collaboration and supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA) on 7th Feb. Under the agreement, WMBIO will sponsor the Phase 1 (or Phase 1b) clinical trial for WM-A1-3389, a novel therapeutic antibody for Non-Small Cell Lung Cancer (NSCLC) patients with low or no PD-L1 expression, in combination with KEYTRUDA (pembrolizumab), MSD's anti-PD-1 therapy....WMBIO is also planning to expand the target patient group to other solid tumor indications."
Licensing / partnership • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
1 to 4
Of
4
Go to page
1